$0.149
2.93%
Downside
Day's Volatility :4.34%
Upside
1.45%
38.4%
Downside
52 Weeks Volatility :97.16%
Upside
95.38%
Period | Humanigen Inc | |
---|---|---|
3 Months | -6.29% | |
6 Months | 5.52% | |
1 Year | -93.63% | |
3 Years | -98.46% |
Market Capitalization | 17.7M |
Book Value | - $0.42 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.5 |
Wall Street Target Price | 0.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -3061.21% |
Return On Assets TTM | -85.05% |
Return On Equity TTM | -2165.43% |
Revenue TTM | 1.7M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -78.7% |
Gross Profit TTM | -209.5M |
EBITDA | -9.0M |
Diluted Eps TTM | -0.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.15 |
EPS Estimate Next Year | -0.09 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 121.48%
Sell
Neutral
Buy
Humanigen Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Humanigen Inc | -0.6% | 5.52% | -93.63% | -98.46% | -98.46% |
![]() Moderna, Inc. | 0.28% | -25.82% | -4.84% | 117.92% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -7.87% | -2.05% | 21.5% | 22.45% | 137.1% |
![]() Seagen, Inc. | -1.61% | 61.18% | 37.09% | 26.01% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.63% | 5.09% | 23.88% | 20.49% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Humanigen Inc | NA | NA | NA | -0.15 | -21.65 | -0.85 | 0.0 | -0.42 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Humanigen Inc | Sell | $17.7M | -98.46% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
BlackRock Inc
Bank of New York Mellon Corp
Vanguard Group Inc
Geode Capital Management, LLC
Telemetry Investments, L.L.C.
UBS Group AG
Humanigen Inc’s price-to-earnings ratio stands at None
Read MoreHumanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.
Organization | Humanigen Inc |
Employees | 6 |
CEO | Dr. Cameron Durrant M.D., MBA |
Industry | Biotechnology |
ProShares Bitcoin Strategy ETF
$15.29
+1.8%
Invesco Dynamic Software ETF
$105.19
+0.54%
ARROWROOT ACQUISITION CORP-A
$10.38
-0.09%
SimilarWeb Ltd
$6.74
+3.37%
Rimini Street Inc
$4.29
+1.66%
SENTI BIOSCIENCES INC
$0.93
+5.87%
WISDOMTREE US EFFICIENT CORE
$36.20
+0.84%
XOMA CORP
$17.97
+5.64%
Madison Square Garden Entertainment Corporation
$40.09
+9.48%